Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results

The key exclusion criteria were history of polymerase chain reaction[-]confirmed COVID-19 or positive test for severe acute respiratory syndrome coronavirus 2[-]specific IgG or IgM in the serum. The clinical trial protocol was approved by the Research Ethics Committee of Hong Kong Sanatorium and Hos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hong Kong Medical Journal 2021-08, Vol.27 (4), p.312-313
Hauptverfasser:	Zee, J S T, Lai, K T W, Ho, M K S, Leung, A C P, Chan, Q W L, Ma, E S K, Lee, K H, Lau, C C, Yung, R W H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies Antibodies, Neutralizing - blood BNT162 Vaccine Coronaviruses COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Disease control Female Health Personnel - statistics & numerical data Hong Kong - epidemiology Humans Immunization Immunogenicity, Vaccine Immunoglobulin G - blood Immunoglobulins Infections Male Medical personnel Middle Aged mRNA Vaccines SARS-CoV-2 Serologic Tests - methods Serologic Tests - statistics & numerical data Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - immunology Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The key exclusion criteria were history of polymerase chain reaction[-]confirmed COVID-19 or positive test for severe acute respiratory syndrome coronavirus 2[-]specific IgG or IgM in the serum. The clinical trial protocol was approved by the Research Ethics Committee of Hong Kong Sanatorium and Hospital Medical Group (Ref: RC-2021-07). Of the 457 HCWs recruited, 220 (48.1%) selected an inactivated vaccine (CoronaVac; Sinovac Life Sciences, Beijing, China) and 237 (51.9%) selected an mRNA vaccine (BNT162b2/Comirnaty; Fosun-BioNTech Pharma), based on their personal preference.
ISSN:	1024-2708 2226-8707
DOI:	10.12809/hkmj219605